ARTCLINE Appoints New Chairman and Gears Up for Sepsis Therapy Launch

ARTCLINE GmbH, a biomedical company in Germany, has named Peter Llewellyn-Davies as the Chairman of its Supervisory Board, effective January 1, 2026. This move is part of ARTCLINE's strategy to commercialize its innovative sepsis therapy, ARTICE®, targeting immune dysfunction in septic shock. The therapy is slated for a broad market launch in the second half of 2026.

Llewellyn-Davies, a notable figure in European biotech, brings decades of experience to the role. His career includes founding BIOTECH AUSTRIA and acting as CEO of Accellerate Partners and APEIRON Biologics. His expertise is anticipated to guide ARTCLINE during this critical commercialization phase.

The ARTICE® therapy, which uses allogeneic donor immune cells, is undergoing a multicenter study with results expected by year-end 2026. Regulatory approval for the therapy components is already in place for use in Germany.